A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies

Update Il y a 4 ans
Reference: EUCTR2016-002831-14

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine the pharmacologically active dose (PAD) and maximum tolerated dose (MTD) of INCB054828, alone as a monotherapy and in combination with other therapies. To assess the pharmacodynamics (PD) of INCB054828.


Inclusion criteria

  • advanced malignancies

Links